Jubilant Pharmova (BOM:530019) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


BOM:530019 Jubilant Pharmova Ltd BOM:530019
76 GF Score
Price ₹968.75
GF Value ₹1,054.41
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Jubilant Pharmova Research & Development?

Jubilant Pharmova BOM:530019 -0.40% 76 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:530019 with a GF Score™ of 76/100 and a GF Value™ of ₹1,054.41 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Jubilant Pharmova's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Jubilant Pharmova  (BOM:530019) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Jubilant Pharmova Research & Development Related Terms

Jubilant Pharmova Research & Development Historical Data

* Premium members only.

The historical data trend for Jubilant Pharmova's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jubilant Pharmova Research & Development Chart

Jubilant Pharmova Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Jubilant Pharmova Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:530019
76GF Score
Jubilant Pharmova Ltd BOM:530019
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jubilant Pharmova Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Jubilant Pharmova (BOM:530019) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Jubilant Pharmova and its competitors.
Is Jubilant Pharmova's Research & Development too high?
Jubilant Pharmova's current Research & Development is ₹0 Mil. Overall, Jubilant Pharmova has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's Research & Development compare to ZTS and UTHR?
Jubilant Pharmova's Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Jubilant Pharmova and its competitors. Jubilant Pharmova's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,054.41, compared to a current price of ₹968.75 — trading 8.1% below its estimated fair value. The current Research & Development is ₹0 Mil. Jubilant Pharmova's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?

Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued. The current stock price of ₹968.75 is trading 8.1% below its estimated GF Value™ of ₹1,054.41. GuruFocus considers Jubilant Pharmova to be Fairly Valued.

Key valuation signals for BOM:530019:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹1,054.41 vs. price of ₹968.75 (8.1% below fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jubilant Pharmova Business Description

Other Exchanges JUBLPHARMA:India
Address 1A, Sector 16A, Noida, UP, IND, 201301
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
76GF Score

Get the complete analysis for BOM:530019

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹968.75
Price
₹1,054.41
GF Value